Literature DB >> 15063577

Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A.

Lorrie Tiberio1, Leah Fletcher, John H Eldridge, David D Duncan.   

Abstract

The aim of this study was to determine if certain genotypes might be associated with variable responses to the candidate vaccine adjuvants RC529 and monophosphoryl lipid A (MPL), as well as to bacterial LPS, a structurally similar control stimulus. In this study, the +896 TLR4 polymorphism and selected cytokine polymorphisms were genotyped, and together with the donor sex, these factors were used to model the in vitro cytokine responses to RC529, MPL, and LPS. We show evidence that each of the three stimuli engage human TLR4, that each gave higher responses in men than women, and that TLR4 expression levels in blood monocytes were higher in men than women. From 74 to 92% of the response variation in the whole blood assay was between subjects, yet the multifactorial analyses accounted for only 3-18% of the variation within the study. Potentially there was a sex-dependent TLR4 effect since there was a significant sex-TLR4 interaction term in the multifactorial model for some responses. Since the genotypes we analyzed had such a modest impact in the study, we anticipate that +896 TLR4 genotype and the other factors analyzed in this study have only incremental effects in determining the overall response to TLR4-engaging stimuli.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063577     DOI: 10.1016/j.vaccine.2003.10.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Multivariate analysis of cytokine responses identifies distinctive sensitivities to lipopolysaccharide in humans.

Authors:  David D Duncan; Lorrie Tiberio; John H Eldridge
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

2.  Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.

Authors:  Pernille Nordly; Else Marie Agger; Peter Andersen; Hanne Mørck Nielsen; Camilla Foged
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

Review 3.  The role of Toll-like receptor 4 polymorphisms in vaccine immune response.

Authors:  P Pellegrino; F S Falvella; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2015-03-31       Impact factor: 3.550

4.  Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.

Authors:  Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Bradley Fox; Sofia Scholar; Jeffrey Rosen; Nahida Chakhtoura; Marie Lebacq; Robbert van der Most; Philippe Moris; Sandra L Giannini; Anne Schuind; Sanjoy K Datta; Dominique Descamps
Journal:  Hum Vaccin       Date:  2011-12-01

Review 5.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 6.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

Review 7.  Functional consequences of toll-like receptor 4 polymorphisms.

Authors:  Bart Ferwerda; Matthew Bb McCall; Karlijn Verheijen; Bart-Jan Kullberg; André Jam van der Ven; Jos Wm Van der Meer; Mihai G Netea
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

8.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy.

Authors:  Stacey L Demento; Stephanie C Eisenbarth; Harald G Foellmer; Craig Platt; Michael J Caplan; W Mark Saltzman; Ira Mellman; Michel Ledizet; Erol Fikrig; Richard A Flavell; Tarek M Fahmy
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641

Review 9.  Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?

Authors:  Babak Jalilian; Stig Hill Christiansen; Halldór Bjarki Einarsson; Mehdi Rasoli Pirozyan; Eskild Petersen; Thomas Vorup-Jensen
Journal:  Mol Cell Ther       Date:  2013-11-06

10.  HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells.

Authors:  Johan M J Van den Bergh; Khadija Guerti; Yannick Willemen; Eva Lion; Nathalie Cools; Herman Goossens; Alex Vorsters; Viggo F I Van Tendeloo; Sébastien Anguille; Pierre Van Damme; Evelien L J M Smits
Journal:  J Cell Mol Med       Date:  2014-06-30       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.